Nanjing Frontier Biotech In-licenses Novel Patch Pain Product

Nanjing Frontier Biotechnologies gained global rights to a novel topical patch for acute and chronic pain management from ABsize Inc. of Japan. The product, AB001, has completed a Phase I trial in the US. AB001 is a prescription-strength NSAID topical patch to treat acute pain and inflammation of the joints and muscles. ABsize is a spin-off from Osaka University with a novel nanosizing process that allows patch delivery. More details.... Share this with colleagues: // //